{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:37:43Z","timestamp":1784972263838,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T00:00:00Z","timestamp":1289433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00280-010-1510-y","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T14:33:49Z","timestamp":1289399629000},"page":"457-463","source":"Crossref","is-referenced-by-count":9,"title":["Phase 1\/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer"],"prefix":"10.1007","volume":"68","author":[{"given":"Eleni","family":"Andreopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Liebes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wallach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Hochster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,11]]},"reference":[{"issue":"1","key":"1510_CR1","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1):1\u201311","journal-title":"Cancer Treat Rep"},{"issue":"3","key":"1510_CR2","first-page":"1426","volume":"43","author":"SB Howell","year":"1983","unstructured":"Howell SB, Pfeifle CE, Wung We, Olshen RA (1983) Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43(3):1426\u20131431","journal-title":"Cancer Res"},{"issue":"1","key":"1510_CR3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1006\/gyno.1999.5532","volume":"75","author":"JS Berek","year":"1999","unstructured":"Berek JS, Markman M, Stonebraker B et al (1999) Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study. Gynecol Oncol 75(1):10\u201314","journal-title":"Gynecol Oncol"},{"issue":"9","key":"1510_CR4","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.1995.13.9.2238","volume":"13","author":"RJ Morgan Jr","year":"1995","unstructured":"Morgan RJ Jr, Margolin K, Raschko J et al (1995) Phase I trial of carboplatin and infusional cyclosporin in advanced malignancy. J Clin Oncol 13(9):2238\u20132246","journal-title":"J Clin Oncol"},{"key":"1510_CR5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1158\/1078-0432.CCR-06-1735","volume":"13","author":"RJ Morgan Jr","year":"2007","unstructured":"Morgan RJ Jr, Synold TW, Xi B et al (2007) Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 13:1232\u20131237","journal-title":"Clin Cancer Res"},{"issue":"16 Pt 1","key":"1510_CR6","first-page":"5896","volume":"9","author":"RJ Morgan Jr","year":"2003","unstructured":"Morgan RJ Jr, Doroshow JH, Synold T et al (2003) Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 9(16 Pt 1):5896\u20135901","journal-title":"Clin Cancer Res"},{"key":"1510_CR7","doi-asserted-by":"crossref","unstructured":"Choi MK, Ahn BJ, Yim DS et al (2010) Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. Cancer Chemother Pharmacol Mar 6 [Epub ahead of print]","DOI":"10.1007\/s00280-010-1272-6"},{"issue":"1","key":"1510_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0090-8258(92)90481-W","volume":"45","author":"RF Ozols","year":"1992","unstructured":"Ozols RF (1992) Intraperitoneal salvage chemotherapy in ovarian cancer: who is left to treat? Gynecol Oncol 45(1):1\u20132","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1510_CR9","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.1991.9.8.1510","volume":"9","author":"FM Muggia","year":"1991","unstructured":"Muggia FM, Alberts DS (1991) Intraperitoneal therapy in ovarian cancer: time\u2019s not up (letter). J Clin Oncol 9(8):1510\u20131516","journal-title":"J Clin Oncol"},{"key":"1510_CR10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/oxfordjournals.annonc.a058246","volume":"3","author":"FM Muggia","year":"1992","unstructured":"Muggia FM (1992) More on intraperitoneal therapy (letter). Ann Oncol 3:492","journal-title":"Ann Oncol"},{"key":"1510_CR11","unstructured":"NCI Clinical Alert on Intraperitoneal Therapy of Ovarian Cancer (2006) Jan 4"},{"issue":"26","key":"1510_CR12","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(26):1950\u20131955","journal-title":"N Engl J Med"},{"issue":"1","key":"1510_CR13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34\u201343","journal-title":"N Engl J Med"},{"key":"1510_CR14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group. J Clin Oncol 19:1001\u20131007","journal-title":"J Clin Oncol"},{"key":"1510_CR15","doi-asserted-by":"crossref","unstructured":"Jaaback K, Johnson N (2006) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev (1):CD005340","DOI":"10.1002\/14651858.CD005340.pub2"},{"issue":"4","key":"1510_CR16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/cncr.22466","volume":"109","author":"L Elit","year":"2007","unstructured":"Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM (2007) Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 109(4):692\u2013702","journal-title":"Cancer"},{"key":"1510_CR17","unstructured":"United States National Library of Medicine, National Institutes of Health (2005) NCI Issues Clinical Announcement for preferred method of treatment for Advanced Ovarian Cancer. http:\/\/www.nlm.nih.gov\/databases\/alerts\/ovarian_ip_chemo.html accessed Jan 2010"},{"issue":"suppl 2","key":"1510_CR18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1525-1438.2003.13360.x","volume":"13","author":"M Piccart","year":"2003","unstructured":"Piccart M, Floquet A, Scarfone G et al (2003) Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized Phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer 13(suppl 2):196\u2013203","journal-title":"Int J Gynecol Cancer"},{"key":"1510_CR19","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1200\/JCO.2009.23.6653","volume":"27","author":"WP McGuire","year":"2009","unstructured":"McGuire WP (2009) Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. J Clin Oncol 27:4633\u20134634","journal-title":"J Clin Oncol"},{"key":"1510_CR20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/gyno.1996.0163","volume":"61","author":"FM Muggia","year":"1996","unstructured":"Muggia FM, Liu PY, Alberts DS et al (1996) Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy. Gynecol Oncol 61:395\u2013402","journal-title":"Gynecol Oncol"},{"key":"1510_CR21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1006\/gyno.1993.1198","volume":"50","author":"FM Muggia","year":"1993","unstructured":"Muggia FM, Groshen S, Russell C et al (1993) Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens. Gynecol Oncol 50:232\u2013238","journal-title":"Gynecol Oncol"},{"key":"1510_CR22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.20.3.694","volume":"20","author":"RR Barakat","year":"2002","unstructured":"Barakat RR, Sabbatini P, Bhaskaran D et al (2002) Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow up. J Clin Oncol 20:694\u2013698","journal-title":"J Clin Oncol"},{"issue":"4","key":"1510_CR23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0889-8588(03)00059-5","volume":"17","author":"MJ Lu","year":"2003","unstructured":"Lu MJ, Sorich J, Hazarika M et al (2003) Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy. Hematol Oncol Clin North Am 17(4):969\u2013975","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"1510_CR24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1006\/gyno.1997.4778","volume":"66","author":"F Muggia","year":"1997","unstructured":"Muggia F, Jeffers S, Muderspach L et al (1997) Phase I\/II study of intraperitoneal floxuridine and platinum (cisplatin and\/or carboplatin). Gynecol Oncol 66(2):290\u2013294","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1510_CR25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0090-8258(92)90259-L","volume":"46","author":"J Menczer","year":"1992","unstructured":"Menczer J, Ben-Baruch G, Rizel S, Brenner H (1992) Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission. Gynecol Oncol 46(2):222\u2013225","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1510_CR26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00000421-199202000-00002","volume":"15","author":"A Gramont De","year":"1992","unstructured":"De Gramont A, Demuynck B, Louvet C et al (1992) Survival with intraperitoneal cisplatin in advanced ovarian cancer after second look laparotomy. Am J Clin Oncol 15(1):7\u201311","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"1510_CR27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/gyno.1993.1212","volume":"50","author":"HM Tarraza Jr","year":"1993","unstructured":"Tarraza HM Jr, Boyce CR, Smith WG et al (1993) Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second look laparotomy. Gynecol Oncol 50(3):287\u2013290","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1510_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/gyno.1998.4973","volume":"69","author":"RR Barakat","year":"1998","unstructured":"Barakat RR, Almadrones L, Venkatraman ES et al (1998) A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 69(1):17\u201322","journal-title":"Gynecol Oncol"},{"issue":"7","key":"1510_CR29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1200\/JCO.2003.07.031","volume":"21","author":"ML Rothenberg","year":"2003","unstructured":"Rothenberg ML, Liu PY, Braly PS et al (2003) Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol 21(7):1313\u20131319","journal-title":"J Clin Oncol"},{"key":"1510_CR30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1749-6632.2000.tb07036.x","volume":"922","author":"F Muggia","year":"2000","unstructured":"Muggia F, Liebes L, Potmesil M et al (2000) Intraperitoneal topoisomerase-I inhibitors: preliminary findings with 9-aminocamptothecin. Ann N Y Acad Sci 922:178\u2013187","journal-title":"Ann N Y Acad Sci"},{"key":"1510_CR31","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1200\/JCO.1996.14.12.3074","volume":"14","author":"EK Rowinsky","year":"1996","unstructured":"Rowinsky EK, Kaufman SH, Baker SD et al (1996) Sequences of topotecan and cisplatin: phase I pharmacologic and in vitro studies to examine sequence dependence. J Clin Oncol 14:3074\u20133084","journal-title":"J Clin Oncol"},{"key":"1510_CR32","first-page":"1245","volume":"3","author":"H Hochster","year":"1997","unstructured":"Hochster H, Liebes L, Speyer J et al (1997) Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin Can Res 3:1245\u20131252","journal-title":"Clin Can Res"},{"issue":"11","key":"1510_CR33","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1054\/bjoc.2001.2161","volume":"85","author":"LS Hofstra","year":"2001","unstructured":"Hofstra LS, Bos AM, de Vries EG et al (2001) A phase I and pharmacokinetic study of intraperitoneal topotecan. Br J Cancer 85(11):1627\u20131633","journal-title":"Br J Cancer"},{"key":"1510_CR34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1023\/A:1006045125018","volume":"16","author":"SC Plaxe","year":"1998","unstructured":"Plaxe SC, Christen RD, O\u2019Quigley J et al (1998) Phase I and pharmacokinetic study of intraperitoneal topotecan. Invest New Drugs 16:147\u2013153","journal-title":"Invest New Drugs"},{"key":"1510_CR35","doi-asserted-by":"crossref","unstructured":"Muntz HG, Malpass TW, McGonigle KG et al (2008) Phase II study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal cancer. Cancer 113:490\u2013496","DOI":"10.1002\/cncr.23576"},{"key":"1510_CR36","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2004.09.088","volume":"22","author":"S Placido De","year":"2004","unstructured":"De Placido S, Scambia G, Di Vagno G et al (2004) Topotecan compared with no therapy after response to surgery and carboplatin\/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22:2635\u20132642","journal-title":"J Clin Oncol"},{"key":"1510_CR37","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","volume":"98","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Weber B, Reuss A et al (2006) Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98:1036\u20131045","journal-title":"J Natl Cancer Inst"},{"key":"1510_CR38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/jpet.108.149443","volume":"329","author":"DK Shah","year":"2009","unstructured":"Shah DK, Shin BS, Veith J, T\u00f3th K, Bernacki RJ, Balthasar JP (2009) Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther 329:580\u2013591","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1510-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1510-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1510-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T09:53:23Z","timestamp":1636797203000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1510-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,11]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["1510"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1510-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,11]]}}}